



BIONIC VISION
TECHNOLOGIES

Bionic Vision Technologies

A World Leader in Retinal Implant Technologies

Bionic Vision Technologies Pty Ltd (BVT) is a privately held Australian company developing technology to restore a sense of vision to the blind.

Our lead product is a retinal prosthesis or 'bionic eye' developed to provide greater independence and mobility to people with advanced Retinitis Pigmentosa.

The bionic eye operates by electrically stimulating the remaining retinal ganglion cells in these patients. The product comprises a system of implanted and body worn components.

BVT controls exclusive worldwide rights to a significant intellectual property portfolio around the production and use of implantable devices for the electrical stimulation of the eye and visual pathways in the brain.

This includes intellectual property generated by Bionic Vision Australia; a national consortium of leading Australian Universities and research institutes funded by the Australian Research Council in 2010.

Following a successful proof of concept patient study from 2012-2014 to establish safety and efficacy of a prototype bionic eye, the consortium continued to investigate and develop the technology.

In March 2017, Hong Kong-based China Huarong International Holdings invested USD 18 million in BVT to develop and commercialise the next generation technology.

BVT is currently conducting a clinical trial of the bionic eye system, with the goal of achieving CE Mark in Europe prior to seeking regulatory approval in other jurisdictions.

The company plans to expand its product pipeline with other devices and therapies to improve and restore vision.

© November 2018

